Roche therapy helps 24 percent of untreated bladder cancer patients: study
A newly approved immunotherapy from Roche Holding proved effective as an initial treatment for some patients with advanced bladder cancer, according to data presented on Sunday. Results of the mid-stage trial could help make the case that the drug, Tecentriq, should become the first option therapy of choice for patients with metastatic bladder cancer, according to a researcher leading the study. Known chemically as atezolizumab, Tecentriq last month won U.S. approval for bladder cancer that had progressed following chemotherapy, becoming the first new drug for the disease in 30 years.